{"id":5427,"date":"2026-07-19T16:00:00","date_gmt":"2026-07-19T16:00:00","guid":{"rendered":"https:\/\/humanbodycalculator.com\/blogs\/?p=5427"},"modified":"2026-07-19T12:56:52","modified_gmt":"2026-07-19T12:56:52","slug":"blood-test-may-predict-alzheimers-up-to-10-years-before-symptoms","status":"publish","type":"post","link":"https:\/\/humanbodycalculator.com\/blogs\/blood-test-may-predict-alzheimers-up-to-10-years-before-symptoms\/","title":{"rendered":"Blood Test May Predict Alzheimer&#8217;s Up to 10 Years Before Symptoms"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">A landmark new study presented at the <a href=\"https:\/\/aaic.alz.org\/releases-2026\/blood-test-p-tau217-predicts-alzheimers-risk.asp\" target=\"_blank\" rel=\"noopener\">Alzheimer&#8217;s Association International Conference (AAIC) 2026<\/a> and simultaneously published in <em>JAMA<\/em> found that a simple blood test measuring a protein called <strong>p-tau217<\/strong> can predict a cognitively healthy older adult&#8217;s risk of developing Alzheimer&#8217;s-related cognitive impairment up to a decade before any symptoms appear. Adults with very high p-tau217 levels had an estimated <strong>78% risk of cognitive impairment within 10 years<\/strong> \u2014 even though they showed no memory or thinking problems at the time of testing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Here&#8217;s why this matters right now:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>This is one of the largest studies of its kind<\/strong>, pooling data from nearly 2,700 cognitively healthy older adults across six research cohorts<\/li>\n\n\n\n<li><strong>The blood test outperformed genetic testing and matched brain imaging<\/strong> for predicting future risk \u2014 without the cost or radiation of a PET scan<\/li>\n\n\n\n<li><strong>It&#8217;s not a screening test you can request today<\/strong> \u2014 even the study&#8217;s own senior author is urging caution about who should get tested, and when<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Below, we break down exactly what the study found, how the blood test stacks up against brain scans, and what experts say you should actually do with this information.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Is the New Alzheimer&#8217;s Blood Test Study?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The study, led by Rachel F. Buckley, PhD, and senior author Dr. Reisa Sperling of the <a href=\"https:\/\/www.massgeneralbrigham.org\/en\/about\/newsroom\/press-releases\/blood-test-predicts-alzheimers-years-before-symptoms\" target=\"_blank\" rel=\"noopener\">Mass General Brigham Neuroscience Institute<\/a>, pooled harmonized data from <strong>2,684 cognitively unimpaired adults<\/strong> with an average age of 70, drawn from six well-established research cohorts, including ADNI, A4\/LEARN, HABS, and WRAP. Participants were tracked for an average of 4.7 years, with some followed for more than a decade \u2014 the earliest enrollments date back to 2004.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Researchers measured each participant&#8217;s baseline plasma p-tau217 level, then tracked who went on to develop cognitive impairment, defined as mild cognitive impairment (MCI), dementia, or a clinical dementia rating of 0.5 or higher. Out of the full group, <strong>478 participants progressed to cognitive impairment<\/strong> during the study period.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How Accurate Is the Alzheimer&#8217;s Blood Test at Predicting Risk?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The results, published in <em>JAMA<\/em>, showed a clear, dose-dependent relationship: the higher a person&#8217;s p-tau217 level at baseline, the higher their risk of developing symptoms later \u2014 even years before anything showed up on a cognitive test.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>P-tau217 Level<\/th><th>Risk of Cognitive Impairment (5 Years)<\/th><th>Risk of Cognitive Impairment (10 Years)<\/th><\/tr><\/thead><tbody><tr><td>Very high<\/td><td>~38%<\/td><td>~78%<\/td><\/tr><tr><td>Moderately elevated<\/td><td>~15%<\/td><td>~45%<\/td><\/tr><tr><td>Average \/ low<\/td><td>Substantially lower<\/td><td>Substantially lower<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">For comparison, someone in the &#8220;very high&#8221; category faced roughly a <strong>1-in-3 chance of cognitive impairment within just five years<\/strong> \u2014 a striking finding for people who, at the time of testing, had no detectable memory or thinking problems at all.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Is p-tau217, and Why Does It Matter?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">P-tau217 stands for <strong>phosphorylated tau at position 217<\/strong>, a specific form of the tau protein that becomes abnormally modified as Alzheimer&#8217;s disease progresses in the brain. It&#8217;s already well established as a biomarker that closely tracks amyloid and tau buildup seen on PET brain scans \u2014 but until this study, its usefulness for predicting long-term outcomes in people who felt completely fine wasn&#8217;t well understood.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">That distinction matters because Alzheimer&#8217;s disease typically begins changing the brain <strong>years, sometimes decades, before symptoms appear<\/strong>. A blood test that can flag risk that early opens the door to prevention research and treatment timing that simply wasn&#8217;t possible when diagnosis depended on waiting for memory loss to show up first.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Blood Test vs. Brain Scans: Which Predicts Better?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">One of the most notable findings: the blood test&#8217;s predictive power held up <strong>independent of amyloid PET imaging and APOE4 genetic status<\/strong> \u2014 meaning it added real, useful information beyond what brain scans and genetic testing already provide. That&#8217;s a meaningful upgrade, since PET scans are expensive, involve radiation, and aren&#8217;t widely accessible, while a blood draw is cheap, fast, and can be done almost anywhere.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Researchers noted that plasma p-tau217 showed <strong>consistent prognostic value across all six cohorts<\/strong> in the study, reinforcing that this isn&#8217;t a one-study fluke but a reproducible pattern across different research populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Is This Blood Test Available Now?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Partially. In May 2025, the FDA cleared the <strong>Lumipulse G pTau217\/\u03b2-Amyloid 1-42 Plasma Ratio<\/strong> test, made by Fujirebio, as the first blood test to aid in diagnosing Alzheimer&#8217;s disease. But that clearance applies to people who are already experiencing cognitive symptoms and are being evaluated by a doctor \u2014 not as a general screening tool for healthy adults with no symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This new AAIC 2026\/JAMA research establishes the test&#8217;s <em>prognostic<\/em> value \u2014 how well it predicts future risk in people who currently feel fine \u2014 which is a different, and newer, use case than diagnosis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Should You Get Tested If You Have No Symptoms?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This is where the researchers themselves urge real caution, and it&#8217;s worth taking seriously.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">&#8220;Wait and get tested when you can potentially do something about it,&#8221; says Dr. Reisa Sperling of the Mass General Brigham Neuroscience Institute, the study&#8217;s senior author. (<a href=\"https:\/\/www.oann.com\/newsroom\/jama-new-alzheimers-blood-test-can-predict-symptoms-at-least-a-decade-before-they-begin\/\" target=\"_blank\" rel=\"noopener\">OANN<\/a>)<\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\">In other words: right now, testing a symptom-free adult and finding elevated p-tau217 wouldn&#8217;t actually change what a doctor recommends, since there&#8217;s no approved treatment specifically for asymptomatic, biomarker-positive individuals yet. The value of this research right now is mostly for <strong>science, not individual decision-making<\/strong> \u2014 it&#8217;s a tool for identifying at-risk people for prevention trials, not a home-testing kit for peace of mind.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">&#8220;Elevated p-tau217 levels may help detect dementia risk years earlier,&#8221; says Rachel F. Buckley, PhD, the study&#8217;s lead author. (<a href=\"https:\/\/www.dementiaresearcher.nihr.ac.uk\/blood-test-may-predict-alzheimers-risk-10-years-early\/\" target=\"_blank\" rel=\"noopener\">NIHR Dementia Researcher<\/a>)<\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\">What This Means for Alzheimer&#8217;s Prevention and Treatment<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Alzheimer&#8217;s disease already affects an estimated <strong>7.4 million Americans<\/strong>, a number projected to nearly double to about 13 million by 2050 without a medical breakthrough, according to the Alzheimer&#8217;s Association. Researchers see this blood test primarily as a way to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Identify cognitively healthy, at-risk adults<\/strong> for enrollment in Alzheimer&#8217;s prevention clinical trials<\/li>\n\n\n\n<li><strong>Guide future treatment and monitoring decisions<\/strong>, once therapies for early-stage, pre-symptomatic disease are further developed<\/li>\n\n\n\n<li><strong>Reduce reliance on costly, invasive testing<\/strong> like PET scans or spinal fluid analysis for research purposes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The researchers describe this as a step toward treating Alzheimer&#8217;s risk more like cardiovascular risk \u2014 where a simple blood measurement (like cholesterol) can flag elevated risk long before a heart attack happens, giving doctors and patients time to act.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Can I get this blood test right now to check my Alzheimer&#8217;s risk?<\/strong> The underlying test (measuring p-tau217) is FDA-cleared, but only for diagnostic use in people already showing cognitive symptoms. Using it purely as a screening tool in healthy, symptom-free adults isn&#8217;t yet a recommended or established practice.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Does a high p-tau217 level mean I will definitely get Alzheimer&#8217;s?<\/strong> No. Even in the &#8220;very high&#8221; risk group, roughly 1 in 5 people did not develop cognitive impairment within 10 years. It&#8217;s a risk estimate, not a diagnosis or a guarantee.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>How is this different from a PET scan for Alzheimer&#8217;s?<\/strong> A PET scan directly images amyloid plaques in the brain, while this blood test measures a protein biomarker that tracks closely with that same pathology. The new research found the blood test adds predictive value even beyond what PET scans and genetic testing show.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Why shouldn&#8217;t healthy people rush to get tested?<\/strong> Because there currently isn&#8217;t an approved treatment specifically for people who test positive but have no symptoms, learning your risk years in advance may cause anxiety without changing your medical care \u2014 which is exactly why the study&#8217;s senior author recommends waiting until testing can meaningfully inform a treatment decision.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">Also Read: <a href=\"https:\/\/humanbodycalculator.com\/blogs\/artificial-sweeteners-and-heart-disease-risk-2026-study-explained\/\">Artificial Sweeteners and Heart Disease Risk: 2026 Study Explained<\/a><\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Disclaimer: The information provided in this article is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician before pursuing Alzheimer&#8217;s-related testing or making decisions based on biomarker results.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A landmark new study presented at the Alzheimer&#8217;s Association International Conference (AAIC) 2026 and simultaneously published in JAMA found that &#8230; <\/p>\n<p class=\"read-more-container\"><a title=\"Blood Test May Predict Alzheimer&#8217;s Up to 10 Years Before Symptoms\" class=\"read-more button\" href=\"https:\/\/humanbodycalculator.com\/blogs\/blood-test-may-predict-alzheimers-up-to-10-years-before-symptoms\/#more-5427\" aria-label=\"Read more about Blood Test May Predict Alzheimer&#8217;s Up to 10 Years Before Symptoms\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":5428,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5427","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","resize-featured-image"],"_links":{"self":[{"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/posts\/5427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/comments?post=5427"}],"version-history":[{"count":1,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/posts\/5427\/revisions"}],"predecessor-version":[{"id":5429,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/posts\/5427\/revisions\/5429"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/media\/5428"}],"wp:attachment":[{"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/media?parent=5427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/categories?post=5427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/tags?post=5427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}